Literature DB >> 7984116

Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders.

R J Pary1.   

Abstract

Few investigators have focused on the response of individuals with mental retardation to clozapine. In the general population, some people who have responded to no other psychotropic have had a tremendous positive response, including increased positive scores "quality of life" measures. Clozapine, however, can cause fatal side effects. At least six people in the United States have died from agranulocytosis despite weekly blood counts. The use of clozapine in the general population was reviewed, potential difficulties in prescribing it for individuals with mental retardation discussed, and three relevant case histories presented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984116

Source DB:  PubMed          Journal:  Ment Retard        ISSN: 0047-6765


  3 in total

1.  Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation.

Authors:  R Hammock; W R Levine; S R Schroeder
Journal:  J Autism Dev Disord       Date:  2001-02

Review 2.  Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities.

Authors:  R Antochi; C Stavrakaki; P C Emery
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

Review 3.  Clozapine for psychotic disorders in adults with intellectual disabilities.

Authors:  Muhammad Ayub; Khalid Saeed; Tariq A Munshi; Farooq Naeem
Journal:  Cochrane Database Syst Rev       Date:  2015-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.